Cargando…

Utility of flouro-deoxy-glucose positron emission tomography/computed tomography in the diagnostic and staging evaluation of patients with primary CNS lymphoma

AIM: To prospectively assess the clinical utility of pretreatment flouro-deoxy-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in patients with primary central nervous system (CNS) lymphoma (PCNSL). MATERIALS & METHODS: Patients with suspected/proven PCNSL underwent bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Meetakshi, Gupta, Tejpal, Purandare, Nilendu, Rangarajan, Venkatesh, Puranik, Ameya, Moiyadi, Aliasgar, Shetty, Prakash, Epari, Sridhar, Sahay, Ayushi, Mahajan, Abhishek, Janu, Amit, Bagal, Bhausaheb, Menon, Hari, Kannan, Sadhana, Krishnatry, Rahul, Sastri, Goda Jayant, Jalali, Rakesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912853/
https://www.ncbi.nlm.nih.gov/pubmed/31779471
http://dx.doi.org/10.2217/cns-2019-0016
Descripción
Sumario:AIM: To prospectively assess the clinical utility of pretreatment flouro-deoxy-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in patients with primary central nervous system (CNS) lymphoma (PCNSL). MATERIALS & METHODS: Patients with suspected/proven PCNSL underwent baseline whole-body 18F-FDG-PET/CT. Maximum standardized uptake value and tumor/normal tissue ratios were compared between CNS lymphoma and other histological diagnoses. RESULTS: The mean maximum standardized uptake value (27.5 vs 18.2; p = 0.001) and mean tumor/normal tissue ratio (2.34 vs 1.53; p < 0.001) of CNS lymphoma was significantly higher than other histologic diagnoses. Five of 50 (10%) patients with biopsy-proven CNS lymphomas had pathologically increased FDG-uptake at extraneuraxial sites uncovering systemic lymphoma. CONCLUSION: Pretreatment whole-body 18F-FDG-PET/CT provides valuable complementary information in the diagnostic and staging evaluation of patients with PCNSL to guide therapeutic decision-making.